Diabetic Macular Oedema, Retina/Vitreous
Read Time: 6 mins

The Treatment of Diabetic Macular Oedema with ILUVIEN® Intravitreal Implant Following Prior Anti-VEGF Therapy – Case Study

Copy Link
Published Online: Dec 26th 2014 European Ophthalmic Review, 2014;8(2):140–4 DOI:
Authors: Fahd Quhill
Quick Links:
Article Information

Diabetic macular oedema (DMO) is the main cause of vision loss in diabetic retinopathy. The ILUVIEN® intravitreal implant, which contains fluocinolone acetonide and is administered by injection into the vitreous cavity, should be considered if the patient is not responding to anti-vascular endothelial growth factor (VEGF) therapy, and the patient fulfils the recommendations of the National Institute for Health and Care Excellence (NICE) Technology Appraisal 301. The efficacy and safety of the ILUVIEN implant has been demonstrated in clinical studies, and a pre-planned subgroup analysis has shown that it is particularly beneficial in patients with chronic DMO. This case study is the first report in the UK of the effectiveness of the ILUVIEN implant in a patient in whom therapy with ranibizumab did not result in sustained improvements in terms of visual outcomes and foveal thickness.


Corticosteroids, ILUVIEN®, fluocinolone acetonide, diabetic macular oedema (DMO)


The International Diabetes Federation (IDF) estimated that 8.3 % of adults (or 382 million) had diabetes in 2013.1 This is significantly higher than previous estimates (2.8 % or 171 million adults).2 Diabetic retinopathy (DR) is a potentially sight-threatening disease affecting the retinal microvasculature and associated with prolonged hyperglycaemia and other conditions linked to diabetes mellitus such as hypertension.3 DR is a chronic progressive disease with a prevalence of 34.6 %.4 The prevalence of DR and new cases of DR varies by country with prevalence ranging from 10 % in Norway to 61 % in South Africa and newly diagnosed cases ranging from 1.5 % in African Americans to 31 % in China.5

DR is a major cause of vision loss and blindness. Global vision loss occurs through the growth of new vessels, leading to intraocular haemorrhage and, in some cases, retinal detachment. Central vision loss is due to localised damage to the macula/fovea of the eye3 as occurs in diabetic macular oedema (DMO) when the macula swells as fluid accumulates. DMO leads to vision loss and blindness in around 20 % of patients with DR.5 These rates are set to rise, with diabetes set to increase to in excess of 592 million within the next 25 years.1

Pathophysiology of Diabetic Macular Oedema

Numerous physiological and molecular factors, including angiogenesis, inflammation and oxidative stress, are involved in DMO pathogenesis.6 At early disease stages, vascular endothelial growth factor (VEGF) is a major factor in driving retinal changes whereas in chronic diseases, such as DMO, heightened inflammation plays a more important role.7,8 Multiple inflammatory cytokines, such as interleukin (IL)-1β, IL-6, IL-8, monocyte chemoattractant protein-1 (MCP-1), interferon-gammainducible protein (IP-10) and VEGF, are upregulated as the severity of DR increases.9 DMO is multi-factorial disease and steroids can provide an effective therapeutic option as they target multiple factors in DMO.10

The ILUVIEN Intravitreal Implant

ILUVIEN is an intravitreal implant containing 190 μg of fluocinolone acetonide (FAc implant). It measures 3.5 mm in length and 0.37 mm in width, and is injected into the vitreous cavity using a 25-gauge needle. The implant releases 0.2 μg/day of fluocinolone acetonide.11 FAc implant is a multi-factorial therapy that offers continuous low-dose therapy for up to 36 months with a single injection.12 The efficacy and safety of FAc implant has been examined in the Pharmacokinetic and Efficacy Study of Fluocinolone Acetonide Implants in Patients with DMO (FAMOUS) and Fluocinolone Acetonide for Diabetic Macular Edema (FAME) clinical trials.12–15 Based on the clinical trial evidence, FAc implant is indicated for treatment of visual impairment due to chronic DMO that is considered insufficiently responsive to available therapies. FAc implant was launched in the UK and Germany in early 2013 and is currently licensed in the UK, Germany, Austria, France, Portugal, Spain, Italy, Norway, Sweden and Denmark with licences pending in several other European countries. Described here, to the best of the author’s current knowledge, is the first case study reporting the UK of the effectiveness of the FAc implant in a patient in whom therapy with ranibizumab did not result in sustained improvements in terms of visual outcomes and foveal thickness.

Clinical Experience

A 68-year-old, white female with type 2 diabetes who had been diagnosed 18 years prior to presentation. She was diagnosed with DMO in the right eye (RE) on 1 October 2008, when visual acuity (VA) was 6/6 in both eyes, and in the left eye (LE) on 20 October 2010. The patient’s DMO was managed with macular laser alone to the RE, and initial macular laser to the LE followed by a single intravitreal triamcinolone acetonide (IVTA). On 2 February 2012, she underwent phacoemulsification and intraocular lens implantation in the LE combined with 4 mg IVTA to treat cataract and recurrent DMO. Table 1 summarises the main data relating to the treatment history of this patient as well the responses of VA, central macular thickness (CmT) and intraocular pressure (IOP).

On 24 September 2012, the patient was admitted into the MATISSE trial, in which patients received six monthly injections with the

small-interfering RNA (siRNA) agent PF-04523655 and ranibizumab or PF-04523655 alone (see Figures 1–3). Major inclusion criteria for this trial were VA in the study eye ≤20/200 and low VA is the result of an irreversible condition affecting the posterior segment of the study eye. On 24 September 2012, vision was recorded as 6/5 RE and 6/30 LE, with a CMT of 805 μm LE. The patient received five injections of combination therapy that started 8th October 2012 and six further injections with ranibizumab alone that started 6 June 2013.

During the combined therapy period (siRNA with ranibizumab) in the LE: IOP decreased from 18 mmHg to 15 mmHg on the 7 January 2013, at which point CMT decreased to 271 μm (–534 μm); and, vision improved to 6/9. At the same time, in the RE, IOP, CMT and vision remained unchanged. Despite combined therapy, the DMO continued progressing as the patient exited the study on 8 April 2013, with CMT increasing to 573 μm (+302 μm from the minimum value achieved [i.e., 271 μm]) in the LE in January 2013.

Upon exiting the 6-month trial, the treating physician applied for funding of additional ranibizumab treatment (i.e. prior to approval by the National Institute for Health and Care Excellence [NICE] technology appraisals [TA301]16) and the patient received six further ranibizumab injections between June 2013 and January 2014 with approximately 6-week intervals between injections. In total, the patient had received 11 injections of ranibizumab in the LE between October 2012 and January 2014 (i.e. over a 16 month period). The patient was assessed in the interim, in September 2013, at which time CMT had improved slightly (i.e. 451 μm). However, vision had declined to 6/36 in the LE.

The patient then presented to the clinic 52 days, after the sixth ranibizumab injection, on 3 March 2014. Her LE VA was 6/24 and CMT was 774 μm. As the DMO had remained refractory to a course of

ranibizumab treatment, she was listed for FAc implant injection in the LE and this was conducted 18 days later.

Response to ILUVIEN

One week after the intravitreal injection, the patient’s LE VA had improved to 6/18; CMT had rapidly decreased from 774 μm to 267 μm (i.e. >500 μm improvement) and decimal vision had improved from 0.25 to 0.33. Further, after an additional 14 days, vision improved to 0.50 (6/12). This represents a gain of 15-letters. This gain in vision was maintained at 6 months.

Five months post-FAc implant insertion, DMO resolution was maintained with stable results on OCT scanning (see Figure 4).

IOP remained within normal limits, no elevations were observed and the patient was not commenced on IOP-lowering therapy. IOP was

unchanged in the 6 months following FAc implant – measuring 17 mmHg prior to FAc implant and 17 mmHg after 3 months.VA in the LE has improved to 6/12 (a gain of 15-letters) at the time of writing and the patient is being monitored on a quarterly basis.

Concluding Remarks

In this case study, the FAc implant swiftly induced complete regression of DMO in the LE of a patient who had ceased to respond to treatment after multiple anti-VEGF injections. FAc implant also rapidly improved vision by 15-letters and reached a vision of 6/12 after 14 days. After receiving FAc implant, the patient’s vision improved to 6/12 (or 0.5) and achieving this is important to the patient as it is a requirement for a driving licence in the UK.17 This case report includes an extended period of follow-up (6 months) and no IOP changes were identified.

This real-use clinical experience of the FAc implant in a patient who did not show an optimal response to anti-VEGF therapy is in line with the evidence reported in the FAME clinical studies. These studies investigated the efficacy and safety of the FAc implant, and pre-planned subgroup analysis revealed that the relative benefit was most substantial in patients with chronic DMO.15 This is the first report of the FAc implant following prior therapy with anti- VEGF therapy and a siRNA agent. The management of this case study was carried out in accordance with the guidance outlined in the NICE Technology Appraisal 301.16

No side effects of the FAc implant were reported in this case; however, the most common side effects reported in the ILUVIEN Summary of Product Characteristics include cataract operation, cataract, increased intraocular pressure and floaters.11

The FAc implant represents an important treatment option that should be considered in a patient who is not responding to anti-VEGF therapy. In such patients, treatment with FAc implant should not be delayed, as the ultimate goal of any treatment for DMO is consistent reduction of oedema to regain and maintain functional benefit. The ideal candidates for intravitreal fluocinolone acetonide are pseudophakic patients with DMO refractive to laser photocoagulation and anti-VEGF therapy

Article Information:

Fahd Quhill has attended advisory boards and speaker engagements and has been remunerated for these by Alimera Sciences.


Fahd Quhill, Department of Ophthalmology, Royal Hallamshire Hospital, Glossop Road, Sheffield, South Yorkshire, S10 2JF, UK. E:


The publication of this article and editorial assistance was funded by Alimera Sciences Ltd. The views and opinions expressed in the article are those of the
authors and not necessarily those of Alimera Sciences Ltd.

Compliance with Ethical Guidance: Procedures were followed in accordance with the responsible committee on human experimentation and with the Helsinki Declaration of 1975 and subsequent revisions. Informed consent was received from all patients involved in the study.


Editorial assistance was provided by Catherine Amey at Touch Medical Media. I also thank my Consultant Ophthalmic colleagues, Chris Brand and
Nachi Acharya, who contributed to the management of this case.




1. IDF Diabetes Atlas. 6th edition: International Diabetes Federation (IDF); 2013. Available from: sites/default/files/EN_6E_Atlas_Full_0.pdf (accessed 19 September 2014).
2. Wild S, Roglic G, Green A, et al., Global prevalence of diabetes: estimates for the year 2000 and projections for 2030, Diabetes Care, 2004;27:1047–53.
3. Diabetic Retinopathy Guidelines. The Royal College of Opthalmologists, 2012 December, 2012 (update to section 14.3.4 in July 2013). Report No.
4. Yau JW, Rogers SL, Kawasaki R, et al., Global prevalence and major risk factors of diabetic retinopathy, Diabetes Care, 2012;35:556–64.
5. Ruta LM, Magliano DJ, Lemesurier R, et al., Prevalence of diabetic retinopathy in Type 2 diabetes in developing and developed countries, Diabet Med, 2013;30:387–98.
6. Ehrlich R, Harris A, Ciulla TA, et al., Diabetic macular oedema: physical, physiological and molecular factors contribute to this pathological process, Acta Ophthalmol, 2010;88:279–91.
7. Tang J, Kern TS, Inflammation in diabetic retinopathy, Prog Retin Eye Res, 2011;30:343–58.
8. Prasad S, Sung B, Aggarwal BB, Age-associated chronic diseases require age-old medicine: role of chronic inflammation, Prev Med, 2012;54 (Suppl.):S29–37.
9. Dong N, Xu B, Wang B, Chu L, Study of 27 aqueous humor cytokines in patients with type 2 diabetes with or without retinopathy, Mol Vis, 2013;19:1734–46.
10. Sohn HJ, Han DH, Kim IT, et al., Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema, Am J Ophthalmol, 2011;152:686–94.
11. Summary of Product Characteristics: Alimera Sciences Limited; 2014 (updated 18 February 2014) Available from: (accessed 8 October 2014).
12. Campochiaro PA, Nguyen QD, Hafiz G, et al., Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants, Ophthalmology, 2013;120:583–7.
13. Campochiaro PA, Hafiz G, Shah SM, et al., Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert, Ophthalmology, 2010;117:1393–9.e3.
14. Campochiaro PA, Brown DM, Pearson A, et al., Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema, Ophthalmology, 2011;118:626–35.e2.
15. Campochiaro PA, Brown DM, Pearson A, et al., Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema, Ophthalmology, 2012;119:2125–32.
16. NICE technology appraisals [TA301]. Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (rapid review of technology appraisal guidance 271) 2013. Available from: Guidance (cited 19 September 2014).
17. Bron AM, Viswanathan AC, Thelen U, et al., International vision requirements for driver licensing and disability pensions: using a milestone approach in characterization of progressive eye disease, Clin Ophthalmol, 2010;4:1361–9.

Further Resources

Share this Article
Related Content In Retina/Vitreous
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72